Phase 1 population

Both solid and haematological tumours, adult

Mechanisms studied

• Taxane
• TKI
• HDAC inhibitors
• Diaphorase inhibitor
• Hsp 90 inhibitor
• Vinca alkaloid
• Broad range of novel immunotherapeutics (vaccines, antibodies, adjuvants)

First-in-Man studies

Yes

Centre specific translational research interest

Yes. Our primary expertise to date has been in the development of early phase immunotherapeutics. We are now actively working on developing strategies to control anti-aptoptotic pathways and are developing novel small molecules for clinical testing.

Multi-centre Phase 1 studies

Yes, with a particular interest in immunotherapeutic and anti-apoptotic pathways.

• Full range of medical imaging: CT, MRI (funding for 3T machine under consideration), CT/PET, Gamma camera (dedicated research machine installed in 2006).
• Wellcome Trust Clinical Research Facility: for the accommodation of patients in early phase studies, including apheresis equipment and sample processing facilities.
• Radiopharmacy: with full MHRA licence for manufacture of immunoconjugates.
• Cellular therapy GMP lab: with full MHRA licence for manufacture and storage.

Tissue Banking Activity

In house tissue bank, for fresh frozen tissue, PBMC, serum, links in with Oncore tissue collection.

Centre contact responsible for sample collection

Mrs. Myra Armstrong
Tel. 02380 796 184

Other equipment/ facilities not available on site

• Mass spectrometry
• Proteomic analysis (university site)
• NMR for structural protein analyses (university site)
• HPLC